RCS - Arecor Therapeutics - Upcoming conference attendance

Arecor Therapeutics

18/05/2026 07:00

RNS Number : 5499E

Arecor Therapeutics PLC

15 May 2026

 

 

Arecor Therapeutics plc

("Arecor" or the "Company")

 

Upcoming conference attendance

Cambridge, UK, 18 May 2026: Arecor Therapeutics plc (AIM: AREC), a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases, will be attending the American Diabetes Association (ADA) 2026 Scientific Sessions and the BIO International Convention in San Diego.

 

American Diabetes Association (ADA) 2026 Scientific Sessions - 5-8 June 2026, New Orleans

Arecor's CEO, Dr Sarah Howell, and CSO, Dr Jan Jezek, will be attending ADA alongside over 12,000 leaders in the diabetes field, to meet with KOLs, researchers and investors.  ADA is the largest meeting in the field of diabetes care, providing a platform for the latest advancements in technology and innovative treatments, including Arecor's lead clinical stage product, AT278.  AT278 is the only ultra-concentrated, ultra-rapid acting insulin designed to accelerate the advancement of the next generation of Automated Insulin Delivery Systems.

 

BIO International Convention - 22-25 June 2026, San Diego

Jalini Gugagayanan, Business Development Manager at Arecor, will be attending the BIO International Convention, to meet potential partners and industry contacts at the largest and most comprehensive event for biotechnology, with over 20,000 industry leaders from around the world in attendance.

 

For attendees at either conference interested in meeting the Arecor team, please email BD@arecor.com.

-ENDS-

For more information, please contact:

 

Arecor Therapeutics plc
 Dr Sarah Howell, Chief Executive Officer
 David Ellam, Chief Financial Officer
+44 (0) 1223 426060
info@arecor.com
Singer Capital Markets Advisory LLP
 (NOMAD and Broker)
+44 (0) 20 7496 3000
Phil Davies, James Fischer
Vigo Consulting (Financial Communications)Melanie Toyne-Sewell, Rozi Morris
+44 (0) 20 7390 0230
arecor@vigoconsulting.com
Vida Strategic Partners (US Investor Relations)
Stephanie Diaz
+1 (415) 675-7401
sdiaz@vidasp.com

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.

Its lead product is AT278, the only ultra-concentrated (500U/mL) ultra-rapid acting insulin, which enables disruptive drug delivery devices. It is being co-developed with Sequel Med Tech, a company commercialising state-of-the art insulin delivery devices. Arecor is also developing a novel oral delivery platform for peptides with its first validation target a GLP-1 receptor agonist.

The Company is quoted on AIM (AIM: AREC) and is based in Cambridge, UK. For further details please see www.arecor.com

Arecor® and Arestat® are registered trademarks of Arecor Limited.

About AT278

AT278 is a novel proprietary formulation of an existing insulin, designed to accelerate the absorption of insulin post injection even at very high concentrations (500U/mL). With its best-in-class profile, it has the potential to disrupt the market for insulin treatment as the first concentrated, yet very rapid acting insulin for the growing population of people with diabetes with high daily insulin needs as well as to act as a critical enabler in the development of next-generation, miniaturised longer wear automated insulin delivery (AID) systems.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NRAEANSSFDEKEEA